Sickle Cell Anemia Testing & Screening Market - Global Forecast 2025-2032

The sickle cell anemia testing & screening market is advancing through rapid innovation and a changing healthcare landscape. Senior decision-makers face evolving challenges and opportunities as they seek to optimize diagnostic strategy, regulatory compliance, and operational efficiency.

Market Snapshot: Global Sickle Cell Anemia Testing & Screening Market

In 2024, the global sickle cell anemia testing & screening market reached a valuation of USD 1.07 billion, with projections pointing to USD 1.21 billion by 2025 and an expected 13.90% compound annual growth rate. Market development is driven by accelerated adoption of innovative diagnostics, an increased focus on newborn and mass population screening efforts, and significant investment in laboratory modernization initiatives. For B2B organizations, this expansion is closely linked to improving diagnostic workflows, enhancing reliability and accessibility, and scaling solutions to meet healthcare system demands in a cost-efficient manner.

Scope & Segmentation: Strategic Market Overview

• Test Types: High-performance liquid chromatography (HPLC) provides precise identification of hemoglobin variants for informed clinical decisions. Immunoassays like ELISA and lateral flow devices enable rapid screening essential in emergency departments and outreach programs. Molecular diagnostics, such as PCR and next-generation sequencing, support genetic confirmation, contributing to both centralized laboratory operations and distributed, field-based diagnostics.
• Product Offerings: Consumables, including test kits and reagents, deliver compatibility across automated lab systems, streamlining workflow and ensuring result consistency. Professional services—such as technical training and after-sales support—ensure reliable system performance, minimize operational risks, and help maintain defined quality standards throughout the diagnostic process.
• End Users: Hospital laboratories, ambulatory clinics, dedicated diagnostic centers, and research institutions utilize these technologies for acute care management, chronic patient monitoring, and robust screening programs. This breadth supports multiple operational models and diverse patient populations within healthcare systems.
• Sample Types: By using capillary and venous blood samples alongside saliva-based testing kits, access is extended from well-equipped urban facilities to remote and resource-limited environments, enhancing early identification and equitable patient reach.
• Distribution Channels: Direct sales representatives, specialized diagnostic distributors, and e-commerce partners ensure widespread market access and supply chain resilience, crucial when timely delivery and operational stability underpin successful diagnostic deployment.
• Regional Markets: The Americas capitalize on established early detection programs and integrated laboratory networks. EMEA emphasizes diagnostics that are standards-compliant and interoperable, with regulatory adherence shaping product adoption. Asia-Pacific continues its development of screening infrastructure and focus on community-level disease management models.
• Leading Companies: Key industry players—including F. Hoffmann-La Roche Ltd, Abbott Laboratories, Thermo Fisher Scientific Inc., Bio-Rad Laboratories, Becton, Dickinson and Company, Siemens Healthineers AG, DiaSorin S.p.A., PerkinElmer, Ortho Clinical Diagnostics, and QIAGEN N.V.—drive technology advancements, workforce education, and distribution reliability.

Key Takeaways for Senior Decision-Makers

• Expanding diagnostic portfolios helps organizations align with updated clinical standards and respond to changing regulatory landscapes, supporting outcome consistency within varied care settings.
• Strategic adoption of digital health—through remote monitoring and telemedicine—extends diagnostic access into remote and underserved regions, broadening the impact of testing initiatives and supporting timely clinical intervention.
• Diversifying supplier networks and building out local manufacturing capacity enhance operational security, reduce exposure to international supply disruptions, and enable sustained compliance even amid regulatory shifts.
• Integrating point-of-care solutions alongside centralized labs allows for greater flexibility between emergency and routine testing, increasing organizational agility and supporting scalable service delivery.
• Collaboration among vendors, laboratories, and research centers accelerates technology deployment and fosters quick adaptation to new clinical guidelines or regulatory frameworks, streamlining implementation and standardizing quality practices.

Tariff Impact on the Sickle Cell Diagnostics Market

Recent U.S. tariffs have elevated the cost of importing sickle cell anemia diagnostic devices, demanding additional compliance and strategic adjustment by market participants. Industry leaders are optimizing manufacturing processes, reinforcing supplier partnerships, and evolving operational strategies to preserve uninterrupted product availability and maintain compliance against a dynamic policy backdrop.

Methodology & Data Sources

This analysis integrates regulatory publications, peer-reviewed studies, national health authority guidelines, and direct interviews with laboratory managers, technology providers, and policy specialists. This diverse set of inputs anchors the findings in reliable data and industry expertise, reflecting current market realities.

Why This Report Matters

• Enables informed resource allocation, competitive market positioning, and strategic diagnostic planning for senior decision-makers in the sickle cell anemia testing & screening market.
• Supports identification and evaluation of potential partnerships, as well as benchmarking against leading operational and technological practices for improved agility and impact.
• Presents a robust, data-led foundation to support evidence-based investment and operational decisions tailored to evolving market demands.

Conclusion

This report equips decision-makers to refine diagnostic strategies, strengthen organizational collaborations, and build resilient healthcare operations as technological progress and regulatory climates continue to influence market direction.

Additional Product Information:

• Purchase of this report includes 1 year online access with quarterly updates.
• This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.